Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy



Status:Active, not recruiting
Conditions:Cardiology, Neurology, Ocular
Therapuetic Areas:Cardiology / Vascular Diseases, Neurology, Ophthalmology
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:October 2011
End Date:December 2016

Use our guide to learn which trials are right for you!

CANOPY: Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy

The objective of the CANOPY trial is to assess the continued safety and effectiveness of the
RX Acculink Carotid Stent System under commercial use in subjects at standard risk for
adverse events from Carotid Endarterectomy (CEA) enrolled by physicians with a range of
carotid stenting experience.


Inclusion Criteria:

1. Subject must be ≥ 18 years of age.

2. Subject does not have any condition that limits their anticipated survival to less
than 3 years.

3. Subject or a legally authorized representative must provide written informed consent
prior to any trial related procedure.

4. Subjects with neurological symptoms within 180 days of the procedure and ≥ 70%
stenosis of the common or internal carotid artery by ultrasound or ≥ 50% stenosis of
the common or internal carotid artery by angiogram - OR-

5. Subjects without neurological symptoms within 180 days of the procedure and ≥ 70%
stenosis of the common or internal carotid artery by ultrasound or ≥ 60% stenosis of
the common or internal carotid artery by angiogram.

6. Subject with all the following target vessel characteristics:

1. Discrete lesion in internal carotid artery (ICA) with or without involvement of
the contiguous common carotid artery (CCA).

2. Vessel diameter ≥ 4.0 mm and ≤ 9.0 mm from reference or contralateral artery.

3. Absence of excessive vessel tortuosity that would impede delivery of devices.

7. Subject must agree not to participate in any other clinical trial for a period of 1
year following the index procedure.

Exclusion Criteria:

1. Subjects with anatomic or clinical conditions which make them at high risk for
adverse events from carotid endarterectomy (CEA).

2. Subject with Hgb <10.g/dl or platelet count < 125,000 µl or has heparin-associated
thrombocytopenia. For subjects on Coumadin (Warfarin) and for subjects with a
platelet or coagulation disorder: Has an international normalized ratio (INR) > 1.5.

3. Subject has active bleeding diathesis or coagulopathy or subject would refuse blood
transfusions.

4. Subject is currently on a list for major organ transplantation (i.e., heart, lung,
liver, kidney) or is being evaluated for such.

5. Subject is currently participating in another clinical trial that has not yet
completed its primary endpoint.

6. Pregnant or nursing subjects and those who plan pregnancy in the period up to 1 year
following index procedure. Female subjects of child-bearing potential must have a
negative pregnancy test done within 7 days prior to the index procedure per site
standard test.
We found this trial at
1
site
Santa Clara, California 95054
?
mi
from
Santa Clara, CA
Click here to add this to my saved trials